Neurocrine Biosciences | NBIX - Los Gastos De Explotación

Precio De Mercado
127.68
Cambio Diario
-2.51 -1.93%
Mensual
-2.63%
Anual
19.63%
Q2 Expectativa
124.95




Los Gastos De Explotación Cambio Fecha
AbbVie USD 10.81B 13.45B 2025-12
Acadia Pharmaceuticals USD 266.6M 23.72M 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
ALKERMES USD 326.44M 1.41B 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amgen USD 5.9B 773M 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Cytokinetics USD 196.12M 27.43M 2025-12
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Exelixis USD 362.75M 21.35M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Prothena USD 27.23M 14.95M 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Repligen USD 177.94M 1.82M 2025-12
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Teva Pharmaceutical Industries USD 4.22B 812M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12
Xoma USD 22.84M 1.67M 2024-09